EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.
By A. Sobrero, J. Maurel, L. Fehrenbacher, W. Scheithauer, Y. Abubakr, M. Lutz, M. E. Vega-Villegas, C. Eng, E. Steinhauer, J. Prausová and 10 more. Journal of Clinical Oncology, 2008
964 citations recorded by the source corpus.
Subfields: Oncology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/30890cf7fe6cae443ac3fe6d12933898e32b1364
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014, background): “In second-line trials, improved RR and PFS have been shown when the anti-EGFR antibodies are combined with an irinotecan-based regimen, although no survival advantage has been demonstrated, probably also because of cross-over to the antiEGFR antibodies in later lines [I, B] [35–37].”
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. (2016, background): “Both EGFR antibodies, cetuximab and panitumumab, have been shown to increase RR and PFS, but not OS when combined with irinotecan-containing therapy in the second-line treatment setting [47, 65, 290] and can be considered if not used previously in the treatment of patients with RAS wild-type disease”
- Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. (2010, result): “These results are comparable to the results of a previous second-line study that evaluated the value of adding cetuximab to irinotecan (350 mg/m(2)).(15,25) In this cetuximab trial, a median PFS difference from 2.”
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2012, neutral): “• FOLFIRI [62] + Bmab [85] ▪ FOLFIRI + Rmab [86] • IRIS (note 6) [87] + Bmab • IRI [88] + Bmab • FOLFIRI (or IRI) + Cmab/Pmab [88, 89]”
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer (2019, neutral): “7 Systemic therapy algorithm for unresectable colorectal cancer 1 3 FOLFIRI + AFL (see comment ⑥) [194] S‑1 + IRI [195] + BEV IRI [196] + BEV [197] FOLFIRI (or IRI) + CET, FOLFIRI + PANI [198, 199] IRI + CET [200] or IRI + PANI [201] Pembro (see comment ⑩) [202] (b) For patients who are refractory o”
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer (2015, background): “It is especially desirable to test for a UGT1A1 genetic polymorphism before administering IRI to patients with a high serum bilirubin level, elderly patients, patients whose general condition is poor (e.g., PS2), and patients for whom severe toxicity (especially neutropenia) developed after the last”
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer (2011, neutral): “(1) FOLFIRI [34] ± bevacizumab, (2) FOLFIRI (or CPT-11 alone) ± cetuximab/panitumumab [46, 47].”